ASSESSMENT (135)SMCL(3) PREPARED IN CHILE FOR THE PALLIATIVE TREATMENT OF METASTATIC BONE PAIN

(153)SmEDTMP was obtained from enriched Sm-152 irradiated at the 5 MW Chilean Research Reactor and labelled at a molar ratio of 15:1 pH 7.5. Biodistribution, autoradiography, radiochemical purity tests were don e for evaluation. 40 patients were treated with 37-55 MBq/kg weight. B one scans using (93m)TcHMDP were obtained prior and after treatment. B one marrow depression was observed in 37% of them and normal liver fun ction ill all of them. In 45% the pain dissapear completely, in 22,5% significantly decreased and Partially ill 30%. In 17 patients more tha n one dosis was injected. Our preliminary results indicate that (153)S mEDTMP is a promising radiotherapeutic agent for palliative treatment of metastatic bone cancer pain and encourage its use specially because it can be produced in countries with law economic resources thus a la rge number of patients can get, the benefits of this new procedure.